Author

Eveline Nueesch

Observed name: E. Nueesch

Institution: Roche (Switzerland)

Observed institution: Roche (Switzerland)

OpenAlex ID: A5031167575

Exposure–response analysis of alectinib in crizotinib-resistant ALK-positive non-small cell lung cancer

2018 · Peter N. Morcos, Eveline Nueesch, et al. · Cancer Chemotherapy and Pharmacology · 30

1025MO First-in-human (FIH) phase I study of RO7122290 (RO), a novel FAP-targeted 4-1BB agonist, administered as single agent and in combination with atezolizumab (ATZ) to patients with advanced solid tumours

2020 · I. Melero, M.F. Sanmamed, et al. · Annals of Oncology · 18

A phase 1b dose-escalation/expansion study of BET inhibitor RO6870810 in patients with advanced multiple myeloma

2021 · Karthik Ramasamy, Ajay Nooka, et al. · Blood Cancer Journal · 16

Alectinib vs crizotinib in treatment-naïve ALK+ NSCLC: CNS efficacy results from the ALEX study

2017 · S. Gadgeel, S. Peters, et al. · Annals of Oncology · 14

Alectinib (ALC) vs crizotinib (CRZ) in treatment-naïve ALK+ non-small-cell lung cancer (NSCLC): Asian vs non-Asian subgroup analysis of the ALEX study

2017 · T.S.K. Mok, S. Peters, et al. · Annals of Oncology · 11

Impact of treatment characteristics on response of different breast cancer subtypes: Pooled multilayer analysis of the German neoadjuvant chemotherapy trials.

2010 · G. Von Minckwitz, M. Untch, et al. · Journal of Clinical Oncology · 8

Open Label, Multicenter, Dose-Escalation/ Expansion Phase Ib Study to Evaluate Safety and Activity of BET Inhibitor RO6870810 (RO), Given As Monotherapy to Patients (pts) with Advanced Multiple Myeloma

2020 · Karthik Ramasamy, Ajay Nooka, et al. · Blood · 5

370 Pharmacodynamic assessment of a novel FAP-targeted 4–1BB agonist, administered as single agent and in combination with atezolizumab to patients with advanced solid tumors

2020 · Victor Moreno, Tatiana Hernandez, et al. · Regular and Young Investigator Award Abstracts · 4

MA 07.01 Patients with ALK IHC-Positive/FISH-Negative NSCLC Benefit from ALK TKI Treatment: Response Data from the Global ALEX Trial

2017 · T. Mok, S. Peters, et al. · Journal of Thoracic Oncology · 4

JCES 01.27 Patients with ALK IHC-Positive/FISH-Negative NSCLC Benefit from ALK TKI Treatment: Response Data from the Global ALEX Trial

2017 · T. Mok, S. Peters, et al. · Journal of Thoracic Oncology · 3

Abstract LB104: Dose-Finding/Expansion Phase Ib Study to Evaluate the Safety and Activity of BET Inhibitor RO6870810 (RO) and Atezolizumab (A) in Patients (pts) with Advanced Ovarian Cancer (OC) or Triple Negative Breast Cancer (TNBC)

2021 · Stephanie Lheureux, Iben Spangaard, et al. · Cancer Research · 2

Bet Inhibitor Rg6146, Venetoclax, and Rituximab Is a Highly Active Regimen in Relapsed/refractory (r/r) Dlbcl: Initial Report of Phase 1b Safety, Biomarker, and Response Data

2019 · M. Dickinson, J. Briones Mejjide, et al. · Hematological Oncology · 1

Works count: 12

Citation count: 116

H-index: 6

I10-index: 5